control group:androgen deprivation therapy

Long time survival of radical prostatectomy in combination with PSMA-SPECT/CT guided radiotherapy of metastatic sites and androgen deprivation therapy compared with androgen deprivation therapy alone in oligo-metastatic prostate cancer: an open-label, phase II, randomized controlled trial.

Long time survival of radical prostatectomy in combination with proton and heavy ion radiotherapy of metastatic sites compared with androgen deprivation therapy alone in oligo-metastatic prostate cancer: an open-label, phase II, randomized controlled trial.